Research Links Glucosamine to Alzheimer’s Disease Progression

A supplement used by many older adults for joint pain might speed up Alzheimer’s progression, according to new findings from the University of Florida. Published on June 9 in Nature Metabolism, the study revealed that people with mild cognitive impairment taking glucosamine supplements had a 25% higher likelihood of developing dementia compared to those who did not.

Additionally, those already diagnosed with Alzheimer’s disease and related dementias showed a 25% increased risk of death linked to glucosamine use.

A Neuropsychologist’s Insight

Dr. Jessica McCarthy, a neuropsychologist from New Jersey, discussed the research with Newsweek. She explained that Alzheimer’s disease results from a mix of amyloid plaques, tau proteins, metabolic dysfunction, and inflammation. Since glucosamine crosses the blood-brain barrier, it may exacerbate an overactive metabolic pathway, worsening disease progression in individuals with mild cognitive impairment and increasing mortality in diagnosed Alzheimer’s patients.

McCarthy mentioned that glucose, in the form of sugar, doesn’t directly cause Alzheimer’s. Still, the brain’s metabolic allocation issues can influence inflammation in Alzheimer’s cases.

She cautioned against taking supplements without understanding their interaction with organs, pre-existing conditions, and other medications. According to McCarthy, this research highlights potential problems.

Understanding Glucosamine

Glucosamine is a popular dietary supplement in the U.S., often used for joint pain and cartilage support. With pervasive use among older adults, the University of Florida research team investigated its possible effects on neurological decline.

The researchers employed artificial intelligence to sort through anonymized patient records from UF Health, spanning 2012 to 2024. They analyzed two groups: those diagnosed with Alzheimer’s and related dementias, and individuals with mild cognitive impairment, which can lead to Alzheimer’s.

Collaborating with Yi Guo and Jiang Bian, the researchers identified 1,896 dementia patients and 2,750 individuals with mild cognitive impairment who used glucosamine. This accounted for about 8% of each group.

After adjusting for factors like age, gender, and demographics, results showed that glucosamine users with mild cognitive issues were significantly more likely to progress to dementia. Additionally, biological mechanisms were explored using brain imaging and mouse models of Alzheimer’s.

Findings indicated that glucosamine might disrupt metabolic processes already altered in Alzheimer’s patients. Notably, increased mortality was observed only in those already diagnosed with dementia, not those with mild cognitive impairment, suggesting varying effects based on disease progression.

Guidance for Glucosamine Users

The researchers noted that the findings are observational and require confirmation through clinical trials. However, the study adds to evidence that metabolic dysfunction is a crucial factor in neurodegenerative diseases.

Dr. McCarthy emphasized the importance of lifestyle modifications for brain and metabolic health. Regular moderate exercise, adequate sleep, a Mediterranean diet, and adhering to prescribed medications are effective strategies for maintaining health and reducing neurodegenerative risks.

Those considering supplements should consult medical professionals. Additionally, a healthy brain requires intellectual and social engagement, good nutrition, and proper rest. These areas are well-supported by research to help manage metabolic health and inflammation.